148 related articles for article (PubMed ID: 28028559)
41. Chronic myeloproliferative diseases.
de Lacerda JF; Oliveira SN; Ferro JM
Handb Clin Neurol; 2014; 120():1073-81. PubMed ID: 24365372
[TBL] [Abstract][Full Text] [Related]
42. Highly increased risk of fracture in patients with myeloproliferative neoplasm.
Johansson P; Kristjansdottir HL; Johansson H; Jakir A; Mellström D; Lewerin C
Leuk Lymphoma; 2021 Jan; 62(1):211-217. PubMed ID: 32909485
[TBL] [Abstract][Full Text] [Related]
43. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
44. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.
Tefferi A; Vardiman JW
Leukemia; 2008 Jan; 22(1):14-22. PubMed ID: 17882280
[TBL] [Abstract][Full Text] [Related]
45. Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study.
Pedersen KM; Bak M; Sørensen AL; Zwisler AD; Ellervik C; Larsen MK; Hasselbalch HC; Tolstrup JS
Cancer Med; 2018 Nov; 7(11):5796-5802. PubMed ID: 30318865
[TBL] [Abstract][Full Text] [Related]
46. Frequency of polycythemia in individuals with normal complete blood cell counts according to the new 2016 WHO classification of myeloid neoplasms.
Sandes AF; Gonçalves MV; Chauffaille ML
Int J Lab Hematol; 2017 Oct; 39(5):528-531. PubMed ID: 28497563
[TBL] [Abstract][Full Text] [Related]
47. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.
Santana-Davila R; Tefferi A; Holtan SG; Ketterling RP; Dewald GW; Knudson RA; Steensma DP; Chen D; Hoyer JD; Hanson CA
Leuk Res; 2008 Dec; 32(12):1927-30. PubMed ID: 18538839
[TBL] [Abstract][Full Text] [Related]
48. Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia.
Malhotra J; Kremyanskaya M; Schorr E; Hoffman R; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):31-6. PubMed ID: 24220620
[TBL] [Abstract][Full Text] [Related]
49. Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms.
Čokić VP; Mitrović-Ajtić O; Beleslin-Čokić BB; Marković D; Buač M; Diklić M; Kraguljac-Kurtović N; Damjanović S; Milenković P; Gotić M; Raj PK
Mediators Inflamm; 2015; 2015():453020. PubMed ID: 26491227
[TBL] [Abstract][Full Text] [Related]
50. Pathology consultation on myeloproliferative neoplasms.
Schmidt AE; Oh ST;
Am J Clin Pathol; 2012 Jul; 138(1):12-9. PubMed ID: 22706852
[TBL] [Abstract][Full Text] [Related]
51. Environmental Factors, Lifestyle Risk Factors, and Host Characteristics Associated With Philadelphia Negative Myeloproliferative Neoplasm: A Systematic Review.
Allahverdi N; Yassin M; Ibrahim M
Cancer Control; 2021; 28():10732748211046802. PubMed ID: 34645293
[TBL] [Abstract][Full Text] [Related]
52. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
53. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
Tefferi A
Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
[TBL] [Abstract][Full Text] [Related]
54. [Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms].
Kerguelén Fuentes AE; Hernández-Maraver D; Lombardia L; Canales Albendea MA; Rodriguez de la Rúa A
Med Clin (Barc); 2012 Oct; 139(9):373-8. PubMed ID: 22743278
[TBL] [Abstract][Full Text] [Related]
55. Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper.
Barosi G; Vannucchi AM; De Stefano V; Pane F; Passamonti F; Rambaldi A; Saglio G; Barbui T; Tura S
Leuk Res; 2014 Feb; 38(2):155-60. PubMed ID: 24378116
[TBL] [Abstract][Full Text] [Related]
56. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.
Hultcrantz M; Kristinsson SY; Andersson TM; Landgren O; Eloranta S; Derolf AR; Dickman PW; Björkholm M
J Clin Oncol; 2012 Aug; 30(24):2995-3001. PubMed ID: 22802311
[TBL] [Abstract][Full Text] [Related]
57. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
Cytometry B Clin Cytom; 2015; 88(4):236-43. PubMed ID: 25557358
[TBL] [Abstract][Full Text] [Related]
58. Aetiology of Myeloproliferative Neoplasms.
McMullin MF; Anderson LA
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32640679
[TBL] [Abstract][Full Text] [Related]
59. BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms.
Koopmans SM; Schouten HC; van Marion AM
Histol Histopathol; 2015 Feb; 30(2):151-61. PubMed ID: 25196073
[TBL] [Abstract][Full Text] [Related]
60. Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up.
Ejerblad E; Kvasnicka HM; Thiele J; Andreasson B; Björkholm M; Löfvenberg E; Markevärn B; Merup M; Nilssson L; Palmblad J; Samuelsson J; Birgegård G
Hematology; 2013 Jan; 18(1):8-13. PubMed ID: 22990042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
